Previous work has shown that inhibiting BACE1 leads to a significant decrease in cerebral Aβ levels, and a lack of BACE1 improved memory impairments in a mouse model of AD without causing significant adverse effects [66,67]. This evidence concerns the gene BACE1 and Alzheimer disease.